Literature DB >> 1942336

Integral laser photodynamic treatment of refractory multifocal bladder tumors.

K Naito1, H Hisazumi, T Uchibayashi, T Amano, A Hirata, K Komatsu, T Ishida, N Miyoshi.   

Abstract

Integral photodynamic therapy with hematoporphyrin derivative was performed on 35 patients who had resistant transitional cell carcinoma of the bladder, mainly carcinoma in situ. The light source was an argon ion pumped dye laser (wavelength 630 nm.) using rhodamine B. Two types of laser light scattering diffuser developed at our department were used: a motor driven laser light scattering diffuser with computer regulation, and an endoscope modified light scattering diffuser tipped with a small quartz bulb containing a lipid nutritious solution as the scattering medium. The total energy density used was 10 to 30 J./cm.2. Of the 35 patients 24 (68.6%) achieved a complete response and 5 (14.3%) a partial response at 3 months. In 10 of the 24 patients there was no recurrence with an average tumor-free interval of 20.9 +/- 16.7 months, ranging from 5 to 60 months. Bladder capacity was decreased to approximately 150 ml. for 3 months after the integral photodynamic therapy without any evidence of hydronephrosis on excretory urograms, except for 2 patients who had a contracted bladder before photodynamic therapy. Integral photodynamic therapy may prove to be useful for the treatment of carcinoma in situ of the bladder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942336     DOI: 10.1016/s0022-5347(17)38160-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Topical anaesthesia for bladder biopsies and cautery: intravesical lidocaine versus caudal anaesthesia.

Authors:  T Amano; M Ohkawa; K Kunimi; Y Oshinoya; T Uchibayashi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

2.  Possible advantages of aluminum-chloro-tetrasulfonated phthalocyanine over hematoporphyrin derivative as a photosensitizer in photodynamic therapy.

Authors:  K Koshida; H Hisazumi; K Komatsu; A Hirata; T Uchibayashi
Journal:  Urol Res       Date:  1993

3.  Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer.

Authors:  R Bachor; R Hautmann; T Hasan
Journal:  Urol Res       Date:  1994

4.  Intravesical therapy for urothelial carcinoma of the bladder.

Authors:  M Manoharan
Journal:  Indian J Urol       Date:  2011-04

5.  Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder.

Authors:  T Uchibayashi; K Koshida; K Kunimi; H Hisazumi
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

Review 6.  Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease.

Authors:  Ryan L Steinberg; Lewis J Thomas; Michael A O'Donnell
Journal:  Bladder Cancer       Date:  2015-10-26

7.  Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitiser dose and time of administration.

Authors:  F A Stewart; Y Oussoren
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  Photodynamic therapy for cancers: a clinical trial of porfimer sodium in Japan.

Authors:  H Kato; T Horai; K Furuse; M Fukuoka; S Suzuki; Y Hiki; Y Ito; S Mimura; Y Tenjin; H Hisazumi
Journal:  Jpn J Cancer Res       Date:  1993-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.